Tecentriq and bevacizumab (atezolizumab & bevacizumab)

pCPA File Number: 21390

Negotiation Status:

Concluded with an LOI

Indication(s):

TECENTRIQ (atezolizumab), in combination with AVASTIN (bevacizumab), for the first-line treatment of adult patients with unresectable or metastatic hepatocellular carcinoma (HCC) who require systemic therapy.

Sponsor/Manufacturer:

HOFFMANN-LA ROCHE LIMITED

CADTH Project Number:

pCODR 10217

pCPA Engagement Letter Issued:

2021-03-26

Negotiation Process Concluded:

2021-10-14